ABSTRACT

Background: Quercetin in combination with polyvinylpyrrolidone (PVP) was found to limit the spreading of necrosis to unaffected tissues in tuberculosis-infected mice. Therefore, we hypothesized that 3D printed medicated skin patch incorporated with a quercetin-PVP combination would provide an appropriate therapeutic drug concentration with desired sustained release profile.

Research design and methods: We fabricated quercetin-PVP 40 extruded-filaments by hot-melt extrusion (HME) technique along with Eudragit® RSPO and tri-ethyl citrate and further printed it to make medicated skin patches using fused deposition modeling (FDM) based 3D Printing technology. Various characterizations were performed to optimize the 3D-printed patch formulation.

Results: Patch formulation has been optimized for several characterization parameters and was further assessed using SEM, DSC, and XRD studies to confirm the conversion of crystalline quercetin into an amorphous form. Finally, the pharmacokinetic profile of an optimized patch was studied in rats showing prolonged T_max, lowered C_max, and reduced fluctuations in plasma concentrations till 18 days with single skin application of 3D-printed medicated patch.

Conclusion: Overall data confirmed the feasibility of developing 3D printed medicated skin patches to provide plasma levels for continued 18 days in rats after a single application.

抽象的

背景：发现槲皮素与聚乙烯吡咯烷酮（PVP）结合可以限制坏死在结核感染小鼠中向未受影响的组织扩散。因此，我们假设掺入槲皮素-PVP组合的3D打印的含药皮肤贴剂将提供具有所需持续释放曲线的合适治疗药物浓度。

研究设计和方法：我们通过热熔挤出（HME）技术，Eudragit®RSPO和柠檬酸三乙酯制备了槲皮素PVP 40挤出丝，并进一步印刷以制成基于熔融沉积模型（FDM）的药皮贴剂。 3D打印技术。进行了各种表征以优化3D打印的贴剂配方。

结果：贴剂的配方已针对多个表征参数进行了优化，并使用SEM，DSC和XRD研究进行了进一步评估，以确认晶体槲皮素已转化为非晶态。最后，在单次皮肤施用3D打印的药物贴剂的情况下，在大鼠中研究了优化的贴剂的药代动力学特征，显示延长的T _max，降低的C _max以及降低的血浆浓度波动，直至18天。

结论：总体数据证实了开发3D打印的含药皮肤贴剂以在大鼠单次使用后连续18天提供血浆水平的可行性。